05:33 PM EDT, 07/23/2024 (MT Newswires) -- Kronos Bio ( KRON ) said late Tuesday the first patient was dosed with the KB-0742 treatment in an expansion group that's enrolling platinum-resistant patients with high-grade serous ovarian cancer.

The patient received a dose of 80mg, given on a four-days-on, three-days-off schedule, the company said.

Kronos Bio ( KRON ) expects to provide an update on the efficacy of KB-0742 in H1 2025, Chief Executive Officer Norbert Bischofberger said in a statement.

The company's shares rose 2.2% in after-hours activity.

Price: 1.4000, Change: +0.03, Percent Change: +2.19